Skip to main content
. Author manuscript; available in PMC: 2024 Mar 22.
Published in final edited form as: Neuropharmacology. 2024 Jan 3;246:109833. doi: 10.1016/j.neuropharm.2023.109833

Fig. 1. CBD attenuates nicotine intake at a low self-administered nicotine dose.

Fig. 1.

(A) Schematic of the experimental design in which mice received vehicle, 40 mg/kg, or 100 mg/kg cannabidiol (CBD) perioral 45 min prior to an intravenous nicotine self-administration session; image created with Biorender.com. (B) Male and female mice self-administering a lower dose of nicotine significantly reduced the number of infusions earned following treatment with 40 or 100 mg/kg CBD. (C) Mice did not differ in the latency to the first nicotine infusion earned following CBD treatment. (D) CBD treatment decreased active lever pressing behavior at both the 40 and 100 mg/kg CBD doses. No statistical differences were observed in inactive lever pressing behavior across treatments. (E) Mice did not differ following CBD treatment in the latency to the first active lever press. Individual data points shown on graphs for each subject. Bar graphs represent mean ± SEM. **p < 0.01, ***p < 0.001, ****p < 0.0001.